<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04915053</url>
  </required_header>
  <id_info>
    <org_study_id>CEIC-2435</org_study_id>
    <nct_id>NCT04915053</nct_id>
  </id_info>
  <brief_title>Black Garlic Nutraceuticals and Blood Pressure Control</brief_title>
  <acronym>ENDOGARLIC</acronym>
  <official_title>Black Garlic Nutraceuticals Supplementation for the Control of Blood Pressure in Hypertension. A Triple-blind Randomized Placebo Control Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitat de Lleida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmactive, S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitat de Lleida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Black garlic contains a series of allyl-sulfur compounds with the ability to modulate nitric&#xD;
      oxide synthetase, angiotensin-converting enzyme system, and endothelial activation, which&#xD;
      together could help better control blood pressure. The main objective of this study is to&#xD;
      evaluate the effect on blood pressure and endothelial health of a daily intake of a black&#xD;
      garlic supplement named ABG (registered mark), which has a higher concentration of black&#xD;
      garlic bioactive compounds, in people with moderate hypertension.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Three measurements, initial, middle, and final.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Random number of samples</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Blood Pressure</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Indirect measure of blood pressure by a trained physician</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Blood nitric oxide content</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Nitric oxide determined by nitrate and nitrite content in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Angiotensin-converting enzyme activity</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Activity measured by a substrate-enzyme activity kit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Endothelial function</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Endothelial blood flow capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood lipid profile</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Analysis of lipid profile (Total-cholesterol, LDL-cholesterol, Triacylglycerides, HDL-Cholesterol)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood cytokine profile</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Analysis of cytokine profile (TNFa, IL-1b, IL-18, IL-6, IL-8, IL-17, IL-23, TGFb) in blood by immunoassays (Multiplexed)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood antioxidant capacity</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Reduction capacity of blood determined by a biochemistry assay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>ABG Black Garlic Extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily intake of a 550 mg tablet, containing 250 mg of Black Garlic Extract and 300 mg of excipients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Daily intake of a 550 mg tablet, containing 250 mg of microcrystalline cellulose and 300 mg of excipients</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ABG+ Black Garlin</intervention_name>
    <description>Daily tablet intake during three months</description>
    <arm_group_label>ABG Black Garlic Extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Crystalline Cellulose</intervention_name>
    <description>Daily tablet intake during three months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Clinical hypertension, medically treated with no more than 2 drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body mass index above 35 kg/m2&#xD;
&#xD;
          -  Fasting blood cholesterol levels below 115 mg/dL&#xD;
&#xD;
          -  Fasting blood glucose levels above 126 mg/dL&#xD;
&#xD;
          -  Taking anyone of the Angiotensin-converting enzyme inhibitors&#xD;
&#xD;
          -  Anemia (hemoglobin below 13 g/dL in men and below 12 g/dL in women)&#xD;
&#xD;
          -  Vitamin or nutraceutical intake in the last 30 days before the study enrollment&#xD;
&#xD;
          -  Chronic gastrointestinal diseases&#xD;
&#xD;
          -  Pregnancy and breastfeeding&#xD;
&#xD;
          -  Garlic allergy&#xD;
&#xD;
          -  Participation in another study 30 days before the study enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel S Portero, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitat de Lleida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcelino Bermúdez, PhD</last_name>
    <phone>+34 973702482</phone>
    <email>mbermudez@irblleida.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jose S Serrano, PhD</last_name>
    <phone>+34 973702408</phone>
    <email>josecarlos.serrano@udl.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Macerlino S Bermudez, PhD</last_name>
      <phone>+34 973702482</phone>
      <email>mbermudez@irblleida.cat</email>
    </contact>
    <contact_backup>
      <last_name>Jose S Serrano Casasola, PhD</last_name>
      <phone>+34 973702408</phone>
      <email>josecarlos.serrano@udl.cat</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitat de Lleida</investigator_affiliation>
    <investigator_full_name>José Serrano</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Garlic</keyword>
  <keyword>Nitric oxide</keyword>
  <keyword>Angiotensin-converting enzyme</keyword>
  <keyword>Antioxidant capacity</keyword>
  <keyword>Endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD data will not be shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

